• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同环糊精衍生物对尼曼-匹克病 C 型治疗中胆固醇的增溶能力。

Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.

机构信息

Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.

Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan.

出版信息

Clin Transl Med. 2023 Aug;13(8):e1350. doi: 10.1002/ctm2.1350.

DOI:10.1002/ctm2.1350
PMID:37620691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10449817/
Abstract

BACKGROUND

Niemann-Pick disease type C (NPC) is a fatal neurodegenerative disorder caused by abnormal intracellular cholesterol trafficking. Cyclodextrins (CDs), the most promising therapeutic candidates for NPC, but with concerns about ototoxicity, are cyclic oligosaccharides with dual functions of unesterified cholesterol (UC) shuttle and sink that catalytically enhance the bidirectional flux and net efflux of UC, respectively, between the cell membrane and the extracellular acceptors. However, the properties of CDs that regulate these functions and how they could be used to improve treatments for NPC are unclear.

METHODS

We estimated CD-UC complexation for nine CD derivatives derived from native α-, β-, and γ-CD with different cavity sizes, using solubility and molecular docking analyses. The stoichiometry and complexation ability of the resulting complexes were investigated in relation to the therapeutic effectiveness and toxicity of each CD derivative in NPC experimental models.

FINDINGS

We found that shuttle and sink activities of CDs are dependent on cavity size-dependent stoichiometry and substituent-associated stability of CD-UC complexation. The ability of CD derivatives to form 1:1 and 2:1 complexes with UC were correlated with their ability to normalize intracellular cholesterol trafficking serving as shuttle and with their cytotoxicity associated with cellular UC efflux acting as sink, respectively, in NPC model cells. Notably, the ability of CD derivatives to form an inclusion complex with UC was responsible for not only efficacy but ototoxicity, while a representative derivative without this ability negligibly affected auditory function, underscoring its preventability.

CONCLUSIONS

Our findings highlight the importance of strategies for optimizing the molecular structure of CDs to overcome this functional dilemma in the treatment of NPC.

摘要

背景

尼曼-匹克病 C 型(NPC)是一种致命的神经退行性疾病,由异常的细胞内胆固醇转运引起。环糊精(CDs)是 NPC 最有前途的治疗候选药物,但由于担心耳毒性,它们是具有双重功能的未酯化胆固醇(UC)穿梭和汇的环状低聚糖,分别催化增强 UC 在细胞膜和细胞外受体之间的双向通量和净外排。然而,调节这些功能的 CDs 的特性以及如何利用它们来改善 NPC 的治疗效果尚不清楚。

方法

我们使用溶解度和分子对接分析,估计了九种源自天然 α-、β-和 γ-CD 的 CD 衍生物与不同腔大小的 UC 的 CD-UC 络合。研究了所得复合物的化学计量和络合能力与每个 CD 衍生物在 NPC 实验模型中的治疗效果和毒性之间的关系。

发现

我们发现 CD 的穿梭和汇活动依赖于腔大小依赖性化学计量和取代基相关的 CD-UC 络合稳定性。CD 衍生物与 UC 形成 1:1 和 2:1 复合物的能力与其作为穿梭物的能力相关,能够正常化细胞内胆固醇转运,以及与其作为汇的细胞 UC 外排的细胞毒性相关,分别在 NPC 模型细胞中。值得注意的是,CD 衍生物与 UC 形成包合物的能力不仅与其疗效相关,还与其耳毒性相关,而没有这种能力的代表性衍生物对听觉功能几乎没有影响,强调了其可预防性。

结论

我们的研究结果强调了优化 CDs 分子结构的策略的重要性,以克服 NPC 治疗中的这种功能困境。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/4cbbc03c771e/CTM2-13-e1350-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/54bded49dd3c/CTM2-13-e1350-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/2a847a8f0d1a/CTM2-13-e1350-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/a555b3357916/CTM2-13-e1350-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/4c740f7a38ca/CTM2-13-e1350-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/7d0886c7cd83/CTM2-13-e1350-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/7c69d111ea0e/CTM2-13-e1350-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/17a792220497/CTM2-13-e1350-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/0fbb156ffe09/CTM2-13-e1350-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/758c1ad803ae/CTM2-13-e1350-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/4cbbc03c771e/CTM2-13-e1350-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/54bded49dd3c/CTM2-13-e1350-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/2a847a8f0d1a/CTM2-13-e1350-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/a555b3357916/CTM2-13-e1350-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/4c740f7a38ca/CTM2-13-e1350-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/7d0886c7cd83/CTM2-13-e1350-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/7c69d111ea0e/CTM2-13-e1350-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/17a792220497/CTM2-13-e1350-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/0fbb156ffe09/CTM2-13-e1350-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/758c1ad803ae/CTM2-13-e1350-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4677/10449817/4cbbc03c771e/CTM2-13-e1350-g001.jpg

相似文献

1
Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.不同环糊精衍生物对尼曼-匹克病 C 型治疗中胆固醇的增溶能力。
Clin Transl Med. 2023 Aug;13(8):e1350. doi: 10.1002/ctm2.1350.
2
Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.经过微调的胆固醇增溶剂单-6-O-α-D-麦芽糖基-γ-环糊精可改善实验性C型尼曼-匹克病且不会导致听力损失。
Biomed Pharmacother. 2022 Nov;155:113698. doi: 10.1016/j.biopha.2022.113698. Epub 2022 Sep 16.
3
Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.胆固醇与 2-羟丙基-β-环糊精包合的差异模式提高了尼曼-匹克病 C 型治疗的安全边际。
Br J Pharmacol. 2021 Jul;178(13):2727-2746. doi: 10.1111/bph.15464. Epub 2021 May 12.
4
[Inclusion Solves Insolubility -Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C].[包容解决不溶性——针对尼曼-匹克病C型的药物开发从床边到实验室再从实验室到床边的转化研究循环]
Yakugaku Zasshi. 2022;142(4):389-400. doi: 10.1248/yakushi.21-00215.
5
Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease.不同环糊精在尼曼-匹克 C 病中的疗效和耳毒性。
Ann Clin Transl Neurol. 2016 Apr 20;3(5):366-80. doi: 10.1002/acn3.306. eCollection 2016 May.
6
Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.羟丙基-β和-γ环糊精通过溶酶体相关膜蛋白 1 挽救尼曼-匹克 C1 突变细胞中的胆固醇积累。
Cell Death Dis. 2018 Oct 3;9(10):1019. doi: 10.1038/s41419-018-1056-1.
7
Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in -Null Cells.2-羟丙基-β-环糊精对-β细胞脂滴积累的差异影响。
Int J Mol Sci. 2020 Jan 30;21(3):898. doi: 10.3390/ijms21030898.
8
Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis.环糊精:评估空腔大小、占据情况和取代基对细胞毒性和胆固醇动态平衡的影响。
Molecules. 2018 May 20;23(5):1228. doi: 10.3390/molecules23051228.
9
Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.基于聚轮烷的β-环糊精系统递送提高尼曼-匹克 C 型疾病小鼠模型治疗效果。
J Control Release. 2018 Jan 10;269:148-158. doi: 10.1016/j.jconrel.2017.11.016. Epub 2017 Nov 11.
10
In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.6-O-α-麦芽寡糖基-β-环糊精作为尼曼-匹克病 C 型潜在治疗药物的体外和体内评价。
Int J Mol Sci. 2019 Mar 6;20(5):1152. doi: 10.3390/ijms20051152.

引用本文的文献

1
Inability of α-cyclodextrins to accommodate cholesterol potentially underlies their lack of efficacy and ototoxicity in Niemann-Pick disease type C treatment.α-环糊精无法容纳胆固醇可能是其在治疗尼曼-匹克病C型时缺乏疗效和存在耳毒性的潜在原因。
Sci Rep. 2025 Aug 22;15(1):30857. doi: 10.1038/s41598-025-15599-0.
2
Cyclodextrins inhibit TRPV1 and TRPA1 activation-induced nociception via cholesterol depletion.环糊精通过消耗胆固醇抑制TRPV1和TRPA1激活诱导的伤害感受。
J Lipid Res. 2025 Jul;66(7):100844. doi: 10.1016/j.jlr.2025.100844. Epub 2025 Jun 16.
3
Polycaprolactone/α-cyclodextrin polyrotaxanes with cellular uptake enhancing properties.

本文引用的文献

1
Cyclodextrins applied to the treatment of lysosomal storage disorders.环糊精在溶酶体贮积症治疗中的应用。
Adv Drug Deliv Rev. 2022 Dec;191:114617. doi: 10.1016/j.addr.2022.114617. Epub 2022 Nov 8.
2
Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.静脉注射2-羟丙基-β-环糊精(Trappsol® Cyclo™)在患有1型尼曼-匹克病的成年受试者的中枢神经系统和外周组织中表现出生物活性并影响胆固醇代谢:1期试验结果。
Mol Genet Metab. 2022 Dec;137(4):309-319. doi: 10.1016/j.ymgme.2022.10.004. Epub 2022 Oct 17.
3
具有增强细胞摄取特性的聚己内酯/α-环糊精聚轮烷
J Mater Chem B. 2025 Mar 5;13(10):3471-3482. doi: 10.1039/d4tb02451f.
4
Current and Emerging Therapies for Lysosomal Storage Disorders.溶酶体贮积症的现有及新兴疗法
Drugs. 2025 Feb;85(2):171-192. doi: 10.1007/s40265-025-02145-5. Epub 2025 Jan 18.
5
β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis.用于治疗动脉粥样硬化的基于β-环糊精的纳米组装体。
Regen Biomater. 2024 Jun 17;11:rbae071. doi: 10.1093/rb/rbae071. eCollection 2024.
6
Impact of cholesterol homeostasis within cochlear cells on auditory development and hearing loss.耳蜗细胞内胆固醇稳态对听觉发育和听力损失的影响。
Front Cell Neurosci. 2024 Jan 4;17:1308028. doi: 10.3389/fncel.2023.1308028. eCollection 2023.
7
Optimization of Antibacterial Activity and Biosafety through Ultrashort Peptide/Cyclodextrin Inclusion Complexes.通过超短肽/环糊精包合物优化抗菌活性和生物安全性。
Int J Mol Sci. 2023 Sep 30;24(19):14801. doi: 10.3390/ijms241914801.
Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
经过微调的胆固醇增溶剂单-6-O-α-D-麦芽糖基-γ-环糊精可改善实验性C型尼曼-匹克病且不会导致听力损失。
Biomed Pharmacother. 2022 Nov;155:113698. doi: 10.1016/j.biopha.2022.113698. Epub 2022 Sep 16.
4
Lactose-Appended Hydroxypropyl-β-Cyclodextrin Lowers Cholesterol Accumulation and Alleviates Motor Dysfunction in Niemann-Pick Type C Disease Model Mice.乳糖修饰的羟丙基-β-环糊精降低尼曼-匹克 C 型疾病模型小鼠的胆固醇蓄积并改善运动功能障碍。
ACS Appl Bio Mater. 2022 May 16;5(5):2377-2388. doi: 10.1021/acsabm.2c00233. Epub 2022 May 4.
5
Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.胆固醇与 2-羟丙基-β-环糊精包合的差异模式提高了尼曼-匹克病 C 型治疗的安全边际。
Br J Pharmacol. 2021 Jul;178(13):2727-2746. doi: 10.1111/bph.15464. Epub 2021 May 12.
6
Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.鞘内注射 2-羟丙基-β-环糊精降低尼曼-匹克病 C 型模型小鼠小脑和肝糖蛋白非转移性黑色素瘤蛋白 B(GPNMB)的表达。
Int J Mol Sci. 2021 Jan 5;22(1):452. doi: 10.3390/ijms22010452.
7
Structural Basis of Low-pH-Dependent Lysosomal Cholesterol Egress by NPC1 and NPC2.NPC1和NPC2介导的低pH依赖性溶酶体胆固醇流出的结构基础
Cell. 2020 Jul 9;182(1):98-111.e18. doi: 10.1016/j.cell.2020.05.020. Epub 2020 Jun 15.
8
Recent developments in the general atomic and molecular electronic structure system.通用原子和分子电子结构系统的最新进展。
J Chem Phys. 2020 Apr 21;152(15):154102. doi: 10.1063/5.0005188.
9
Shuttle/sink model composed of β-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage/foam cells.由β-环糊精和载辛伐他汀的盘状重组高密度脂蛋白组成的穿梭/沉降模型,用于增强巨噬细胞/泡沫细胞中的胆固醇外排和药物摄取。
J Mater Chem B. 2020 Feb 19;8(7):1496-1506. doi: 10.1039/c9tb02101a.
10
Structural Insight into Eukaryotic Sterol Transport through Niemann-Pick Type C Proteins.真核甾醇通过尼曼-匹克 C 型蛋白转运的结构见解。
Cell. 2019 Oct 3;179(2):485-497.e18. doi: 10.1016/j.cell.2019.08.038. Epub 2019 Sep 19.